- Home
- CYCC vs NTRB Comparison
CYCC vs NTRB Comparison
Compare CYCC & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- NTRB
- Stock Information
- Founded
- CYCC 1992
- NTRB 2016
- Country
- CYCC Malaysia
- NTRB United States
- Employees
- CYCC N/A
- NTRB N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- CYCC Health Care
- NTRB Health Care
- Exchange
- CYCC Nasdaq
- NTRB Nasdaq
- Market Cap
- CYCC 61.2M
- NTRB 59.1M
- IPO Year
- CYCC N/A
- NTRB N/A
- Fundamental
- Price
- CYCC $0.32
- NTRB $8.10
- Analyst Decision
- CYCC
- NTRB Buy
- Analyst Count
- CYCC 0
- NTRB 1
- Target Price
- CYCC N/A
- NTRB $13.00
- AVG Volume (30 Days)
- CYCC 3.9M
- NTRB 78.1K
- Earning Date
- CYCC 08-13-2025
- NTRB 05-30-2025
- Dividend Yield
- CYCC N/A
- NTRB N/A
- EPS Growth
- CYCC N/A
- NTRB N/A
- EPS
- CYCC N/A
- NTRB N/A
- Revenue
- CYCC $14,000.00
- NTRB $2,398,437.00
- Revenue This Year
- CYCC $137.21
- NTRB $560.75
- Revenue Next Year
- CYCC N/A
- NTRB $588.39
- P/E Ratio
- CYCC N/A
- NTRB N/A
- Revenue Growth
- CYCC N/A
- NTRB 18.92
- 52 Week Low
- CYCC $0.25
- NTRB $3.72
- 52 Week High
- CYCC $39.84
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- CYCC 25.85
- NTRB 62.62
- Support Level
- CYCC $0.31
- NTRB $7.52
- Resistance Level
- CYCC $0.41
- NTRB $7.80
- Average True Range (ATR)
- CYCC 0.07
- NTRB 0.45
- MACD
- CYCC 0.10
- NTRB -0.03
- Stochastic Oscillator
- CYCC 38.57
- NTRB 69.46
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.